Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.

This approval represents an important step in advancing diabetes care in Canada by bringing an innovative technology to help ...

Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.

The rising popularity of the continuous glucose monitor, which is not the same as an insulin pump, has been a huge advance in ...

PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.

Medtronic is modestly undervalued based on DCF analysis, but slow revenue growth limits upside potential. Read why I ...

The Omnipod 5 App for iPhone is currently compatible with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and is expected to be compatible with the Dexcom G7 CGM in the U.S. in 2025. The ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to recognize National ...

On Sunday, during November's Diabetes Awareness Month, over 1,500 San Diegans walked to raise money to find a cure at the ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today ...